Yes, methylation patterns can serve as biomarkers for cancer detection, diagnosis, prognosis, and treatment response. For instance, the methylation status of the MGMT gene is used to predict the response to alkylating agents in glioblastoma patients. Similarly, hypermethylation of certain genes can be indicative of early-stage cancers.
